Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apricitabine long-term safety extension in HIV-1 infection
ACTRN12606000443594Phase 2Completed
- Sponsor
- Avexa Limited
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apricitabine in human immunodeficiency virus infection (HIV), sponsored by Avexa Limited. Primary endpoints: Time to loss of virologic control and Incidence of adverse events. Started Sep 2006; status: completed.
02
Drugs
apricitabine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ACTRN12606000443594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000443594.